Leading article Hepatitis B virus infection and liver transplantation
Hepatitis B virus (HBV) infection is the commonest cause of chronic liver disease worldwide, and as such, remains an important indication for liver transplantation. Whereas transplantation is an effective treatment for patients with liver failure due to acute and chronic liver diseases, there are subgroups of patients, such as those with HBV infection, who have historically done poorly with transplantation. The five year survival rate for patients undergoing liver transplantation with hepatitis B infection is 50% in the absence of specific prophylactic treatments, compared with survival rates of 700/%-85% for patients with alcoholic or cholestatic liver diseases.' Reduced graft and patient survival in patients with pretransplant HBV infection is largely related to the development of recurrent liver disease.2 I Thus efforts to improve the outcome of HBV infected patients undergoing liver transplantation have focused on strategies to prevent reinfection. In recent years, several new treatments have become available which are improving the outcome of this patient group, lending a sense of optimism to clinicians caring for patients with this disease.
Natural history ofpost-transplantation infection
Early series from the United States and Europe suggested that the level of viral replication before transplantation was important in determining the risk of recurrent disease.2 4 5 In a series of 334 patients from 17 (1) pre-emptive treatment, in which the primary goal is prevention of graft reinfection after transplantation; or as (2) post-transplant treatment for patients with overt recurrence of HBV infection, in which the primary goal is to stabilise graft function and control disease progression. Pre-emptive treatment is an attempt to decrease HBV replication to undetectable levels, with the implication that once achieved, this will substantially reduce the rate of post-transplant infection. In some cases, successful treatment before transplantation may delay or even obviate the need for liver transplantation. Pre-emptive treatment begins before transplantation and continues for variable duration after transplantation.
Interferon-a Interferon-ot (IFN-a.) is an effective antiviral agent in immunocompetent patients with chronic hepatitis B, resulting in a loss of HBeAg and HBsAg more often (20% and 6%, respectively) than in patients given no 27 treatment. It has been used both before and after liver transplantation. 2 28 In a controlled study pre-emptive IFN-ot failed to reduce the rate of HBV reinfection.29 However, rates of recurrence were lower in treated patients who lost HBV DNA prior to transplantation, than in those with ongoing viral replication, suggesting that loss of HBV DNA before transplantation is an important therapeutic end point for pre-emptive treatment. Nucleoside analogues Nucleoside analogues such as lamivudine and famciclovir have engendered much enthusiasm in the transplant setting. Both drugs have potent anti-HBV activity and are given orally.36 37 Lamivudine, the (-) entantiomer of 2'-deoxy-3'-thiacytadine, inhibits the reverse transcriptase of HBV by interfering with synthesis of the proviral DNA chain from viral RNA. Unlike other dideoxynucleosides, lamivudine does not inhibit and is not incorporated into mitochondrial DNA, which has been associated with major toxicities with other nucleoside analogues.38 In the first randomised, placebo controlled, dose ranging study conducted in North America and Europe, lamivudine at doses of 100 mg/day and higher for 28 days, produced a greater than 98% reduction in circulating HBV DNA during treatment.39 Although a breakthrough of HBV DNA did not occur during treatment, HBV DNA rebound was found in most patients after discontinuation of lamivudine.39 In a second randomised study, the efficacy of lamivudine was evaluated over a narrower range of doses (25, 100 and 300 mg daily) and for a longer duration (12 weeks The future The management of HBV infected patients referred for liver transplantation is undergoing an exciting period of change. The positive impact of HBsIg immunoprophylaxis on post-transplant outcome is clearly established but limitations of cost and availability have provided the impetus to find alternatives. The preliminary results with the nucleoside analogues, lamivudine and famciclovir, are encouraging and the final results of the clinical trials which are now in progress are eagerly awaited. Unconsidered issues include (1) the optimal duration of treatment necessary to achieve appropriate treatment end points; (2) elucidation of the mechanisms of treatment failure or "breakthrough"; (3) evaluation of the cost efficacy of specific drug treatments given either alone or in combination. Clinical and virological "breakthroughs" during treatment have been described with HBsIg,8 [22] [23] [24] IFN-a, lamivudine42 45 46 and famciclovir. 44 The aetiology of these breakthroughs is under investigation. Preliminary evidence suggests that mutations in the HBV genome facilitate the "escape" of HBV from the inhibitory effects of the specific treatment, in some cases.457 Full information on the frequency and the clinical consequences of these breakthroughs is awaited. Future therapeutic strategies will likely include several drugs given either concomitantly or sequentially. As more therapeutic options become available, studies on the most cost effective strategy will be needed to guide clinicians in their decision making. 
